Heron Therapeutics’ opioid alternative Zynrelef is not seeing the blockbuster launch some analysts predicted. Commercially launched in July 2021, Zynrelef’s fourth-quarter 2021 sales were just $0.8 million, according to a Feb. 28 earnings release. The drug is currently approved to treat postoperative pain in adult patients following total knee replacement, bunionectomy and groin hernia repair. Under the pharmacy benefit, just 8% of all insured lives have covered or better access to Zynrelef.
SOURCE: MMIT Analytics, as of 3/7/22